Research graph
References from PTH treatment is effective in the Aga2/+ mouse model of moderate to severe osteogenesis imperfecta. Local targets link to admitted publications; unresolved targets remain external evidence.
Osteogenesis imperfecta
10.1016/s0140-6736(04)16051-0 · 2004 · External reference
New perspectives on osteogenesis imperfecta
10.1038/nrendo.2011.81 · 2011 · External reference
Osteogenesis imperfecta and therapeutics
10.1016/j.matbio.2018.03.010 · 2018 · External reference
Homozygous loss-of-function mutations in CCDC134 are responsible for a severe form of osteogenesis imperfecta
10.1002/jbmr.4011 · 2020 · External reference
Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains
1996 · External reference
Dissecting the phenotypic variability of osteogenesis imperfecta
10.1242/dmm.049398 · 2022 · External reference
Bisphosphonate therapy for osteogenesis imperfecta
2016 · External reference
Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties
2017 · External reference
Management of osteogenesis imperfecta
10.3389/fendo.2019.00924 · 2020 · External reference
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women
10.1016/s8756-3282(01)00485-9 · 2001 · External reference
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
10.1016/s8756-3282(00)00376-8 · 2000 · External reference
Fifty years of bisphosphonates: what are their mechanical effects on bone?
10.1016/j.bone.2020.115518 · 2020 · External reference
Catabolic and anabolic actions of parathyroid hormone on the skeleton
2011 · External reference
PTH receptor-1 signalling—mechanistic insights and therapeutic prospects
10.1038/nrendo.2015.139 · 2015 · External reference
PTH1R actions on bone using the cAMP/protein kinase a pathway
10.3389/fendo.2021.833221 · 2022 · External reference
The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats
10.1210/endo.138.11.5505 · 1997 · External reference
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta
10.1172/jci71101 · 2014 · External reference
ER stress-mediated apoptosis in a new mouse model of osteogenesis imperfecta
10.1371/journal.pgen.0040007 · 2008 · External reference
Osteoblast malfunction caused by cell stress response to procollagen misfolding in α2(I)-G610C mouse model of osteogenesis imperfecta
10.1002/jbmr.2824 · 2016 · External reference
4-PBA ameliorates cellular homeostasis in fibroblasts from osteogenesis imperfecta patients by enhancing autophagy and stimulating protein secretion
10.1016/j.bbadis.2018.02.002 · 2018 · External reference
TGF-β type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling
10.1038/ncb2022 · 2010 · External reference
Excessive TGFβ signaling is a common mechanism in osteogenesis imperfecta
10.1038/nm.3544 · 2014 · External reference
Targeting TGF-β for treatment of osteogenesis imperfecta
10.1172/jci152571 · 2022 · External reference
Approach to the patient: pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta
10.1210/clinem/dgad035 · 2023 · External reference
TGF-beta inhibition restores the responsiveness to osteoanabolic PTH treatment in the Crtap−/− model of recessive osteogenesis imperfecta
2018 · External reference
Teriparatide treatment in adult patients with osteogenesis imperfecta type I
10.1007/s00223-013-9770-2 · 2013 · External reference
Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study
10.11138/ccmbm/2017.14.1.153 · 2017 · External reference
Teriparatide plus zoledronic acid for osteogenesis imperfecta: a randomized clinical trial
10.1001/jama.2026.6889 · 2026 · External reference
Guidelines for assessment of bone microstructure in rodents using micro–computed tomography
10.1002/jbmr.141 · 2010 · External reference
Establishing biomechanical mechanisms in mouse models: practical guidelines for systematically evaluating phenotypic changes in the diaphyses of long bones
10.1002/jbmr.2539 · 2015 · External reference
The PERK-EIF2α-ATF4 signaling branch regulates osteoblast differentiation and proliferation by PTH
10.1152/ajpendo.00371.2018 · 2019 · External reference
A chaperone complex formed by HSP47, FKBP65, and BiP modulates telopeptide lysyl hydroxylation of type I procollagen
10.1002/jbmr.3095 · 2017 · External reference
An endoplasmic reticulum stress-specific caspase cascade in apoptosis: cytochrome c-independent activation of caspase-9 by caspase-12
10.1074/jbc.m204973200 · 2002 · External reference
Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress
10.1074/jbc.m010677200 · 2001 · External reference
Caspase-12 and ER-stress-mediated apoptosis: the story so far
10.1196/annals.1299.032 · 2003 · External reference
Caspase-12 processing and fragment translocation into nuclei of tunicamycin-treated cells
10.1038/sj.cdd.4401080 · 2002 · External reference
Parathyroid hormone increases activating transcription factor 4 expression and activity in osteoblasts: requirement for osteocalcin gene expression
10.1210/en.2007-1573 · 2008 · External reference
Parathyroid hormone-stimulation of Runx2 during osteoblast differentiation via the regulation of lnc-SUPT3H-1:16 (RUNX2-AS1:32) and miR-6797-5p
10.1016/j.biochi.2018.12.006 · 2019 · External reference
Regulation of osterix (Osx, Sp7) and the Osx promoter by parathyroid hormone in osteoblasts
2009 · External reference
Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein
10.1074/jbc.m208494200 · 2002 · External reference
Parathyroid hormone on osteoprotegerin levels in patients with primary hyperparathyroidism
10.5152/eurasianjmed.2021.21197 · 2022 · External reference
PTH differentially regulates expression of RANKL and OPG
10.1359/jbmr.0301226 · 2004 · External reference
Anabolic actions of PTH in murine models: two decades of insights
10.1002/jbmr.4389 · 2021 · External reference
PTH treatment increases cortical bone mass more in response to compression than tension in mice
10.1002/jbmr.4728 · 2023 · External reference
Imaging in osteogenesis imperfecta: where we are and where we are going
10.1016/j.ejmg.2024.104926 · 2024 · External reference
PTH and interactions with bisphosphonates
2000 · External reference
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
10.1056/nejmoa031975 · 2003 · External reference
Combination therapy of PTH and antiresorptive drugs on osteoporosis: a review of treatment alternatives
10.3389/fphar.2020.607017 · 2021 · External reference
Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024
10.1093/jbmr/zjae119 · 2024 · External reference
American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update
10.4158/gl-2020-0524suppl · 2020 · External reference
Teriparatide plus zoledronic acid for osteogenesis imperfecta: a randomized clinical trial
10.1001/jama.2026.6889 · ExternalCitation · doi-reference
Guidelines for assessment of bone microstructure in rodents using micro–computed tomography
10.1002/jbmr.141 · ExternalCitation · doi-reference
Establishing biomechanical mechanisms in mouse models: practical guidelines for systematically evaluating phenotypic changes in the diaphyses of long bones
10.1002/jbmr.2539 · ExternalCitation · doi-reference
Osteoblast malfunction caused by cell stress response to procollagen misfolding in α2(I)-G610C mouse model of osteogenesis imperfecta
10.1002/jbmr.2824 · ExternalCitation · doi-reference
A chaperone complex formed by HSP47, FKBP65, and BiP modulates telopeptide lysyl hydroxylation of type I procollagen
10.1002/jbmr.3095 · ExternalCitation · doi-reference
Homozygous loss-of-function mutations in CCDC134 are responsible for a severe form of osteogenesis imperfecta
10.1002/jbmr.4011 · ExternalCitation · doi-reference
Anabolic actions of PTH in murine models: two decades of insights
10.1002/jbmr.4389 · ExternalCitation · doi-reference
PTH treatment increases cortical bone mass more in response to compression than tension in mice
10.1002/jbmr.4728 · ExternalCitation · doi-reference
Teriparatide treatment in adult patients with osteogenesis imperfecta type I
10.1007/s00223-013-9770-2 · ExternalCitation · doi-reference
4-PBA ameliorates cellular homeostasis in fibroblasts from osteogenesis imperfecta patients by enhancing autophagy and stimulating protein secretion
10.1016/j.bbadis.2018.02.002 · ExternalCitation · doi-reference
Parathyroid hormone-stimulation of Runx2 during osteoblast differentiation via the regulation of lnc-SUPT3H-1:16 (RUNX2-AS1:32) and miR-6797-5p
10.1016/j.biochi.2018.12.006 · ExternalCitation · doi-reference
Fifty years of bisphosphonates: what are their mechanical effects on bone?
10.1016/j.bone.2020.115518 · ExternalCitation · doi-reference
Imaging in osteogenesis imperfecta: where we are and where we are going
10.1016/j.ejmg.2024.104926 · ExternalCitation · doi-reference
Osteogenesis imperfecta and therapeutics
10.1016/j.matbio.2018.03.010 · ExternalCitation · doi-reference
Osteogenesis imperfecta
10.1016/s0140-6736(04)16051-0 · ExternalCitation · doi-reference
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
10.1016/s8756-3282(00)00376-8 · ExternalCitation · doi-reference
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women
10.1016/s8756-3282(01)00485-9 · ExternalCitation · doi-reference
TGF-β type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling
10.1038/ncb2022 · ExternalCitation · doi-reference
Excessive TGFβ signaling is a common mechanism in osteogenesis imperfecta
10.1038/nm.3544 · ExternalCitation · doi-reference
New perspectives on osteogenesis imperfecta
10.1038/nrendo.2011.81 · ExternalCitation · doi-reference
PTH receptor-1 signalling—mechanistic insights and therapeutic prospects
10.1038/nrendo.2015.139 · ExternalCitation · doi-reference
Caspase-12 processing and fragment translocation into nuclei of tunicamycin-treated cells
10.1038/sj.cdd.4401080 · ExternalCitation · doi-reference
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
10.1056/nejmoa031975 · ExternalCitation · doi-reference
Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress
10.1074/jbc.m010677200 · ExternalCitation · doi-reference
An endoplasmic reticulum stress-specific caspase cascade in apoptosis: cytochrome c-independent activation of caspase-9 by caspase-12
10.1074/jbc.m204973200 · ExternalCitation · doi-reference
Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein
10.1074/jbc.m208494200 · ExternalCitation · doi-reference
Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024
10.1093/jbmr/zjae119 · ExternalCitation · doi-reference
Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study
10.11138/ccmbm/2017.14.1.153 · ExternalCitation · doi-reference
The PERK-EIF2α-ATF4 signaling branch regulates osteoblast differentiation and proliferation by PTH
10.1152/ajpendo.00371.2018 · ExternalCitation · doi-reference
Targeting TGF-β for treatment of osteogenesis imperfecta
10.1172/jci152571 · ExternalCitation · doi-reference
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta
10.1172/jci71101 · ExternalCitation · doi-reference
Caspase-12 and ER-stress-mediated apoptosis: the story so far
10.1196/annals.1299.032 · ExternalCitation · doi-reference
Approach to the patient: pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta
10.1210/clinem/dgad035 · ExternalCitation · doi-reference
Parathyroid hormone increases activating transcription factor 4 expression and activity in osteoblasts: requirement for osteocalcin gene expression
10.1210/en.2007-1573 · ExternalCitation · doi-reference
The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats
10.1210/endo.138.11.5505 · ExternalCitation · doi-reference
Dissecting the phenotypic variability of osteogenesis imperfecta
10.1242/dmm.049398 · ExternalCitation · doi-reference
PTH differentially regulates expression of RANKL and OPG
10.1359/jbmr.0301226 · ExternalCitation · doi-reference
ER stress-mediated apoptosis in a new mouse model of osteogenesis imperfecta
10.1371/journal.pgen.0040007 · ExternalCitation · doi-reference
Management of osteogenesis imperfecta
10.3389/fendo.2019.00924 · ExternalCitation · doi-reference
PTH1R actions on bone using the cAMP/protein kinase a pathway
10.3389/fendo.2021.833221 · ExternalCitation · doi-reference
Combination therapy of PTH and antiresorptive drugs on osteoporosis: a review of treatment alternatives
10.3389/fphar.2020.607017 · ExternalCitation · doi-reference
American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update
10.4158/gl-2020-0524suppl · ExternalCitation · doi-reference
Parathyroid hormone on osteoprotegerin levels in patients with primary hyperparathyroidism
10.5152/eurasianjmed.2021.21197 · ExternalCitation · doi-reference
